SI-BONE, Inc. Reports Strong Q1 2025 Growth

Si-Bone ( (SIBN) ) has released its Q1 earnings. Here is a breakdown of the information Si-Bone presented to its investors.

SI-BONE, Inc. is a leading medical device company specializing in innovative solutions for sacropelvic disorders, with a strong focus on minimally invasive surgical technologies.

In the first quarter of 2025, SI-BONE reported impressive financial results, showcasing a nearly 25% increase in worldwide revenue and achieving positive adjusted EBITDA. The company continues to demonstrate robust growth and operational efficiency.

Key financial metrics for the quarter included a worldwide revenue of $47.3 million, a 24.9% increase from the previous year, and a U.S. revenue of $44.8 million, up by 26.6%. The gross margin improved to 79.7%, and the net loss decreased by 40% to $6.5 million. Additionally, the company added 300 new active U.S. physicians, marking a 27.3% growth.

SI-BONE’s strategic initiatives, such as the rollout of new products and the proposed New Technology Add-On Payment for iFuse TORQ TNT, are expected to further bolster its market position. The company maintains a strong cash position with $144.4 million in cash and equivalents, reflecting a significant reduction in net cash usage.

Looking ahead, SI-BONE projects continued revenue growth with an updated 2025 guidance of $193.5 million to $197.5 million, and anticipates maintaining a positive adjusted EBITDA for the full year. The company’s focus on innovation and commercial execution positions it well for sustained success in the medical device sector.